The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Slides:

Advertisements

Similar presentations

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Advertisements

Medical Management for BPH: The Role of Combination Therapy

Pascal Rischmann European Urology Supplements

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Volume 57, Issue 5, Pages (May 2010)

Management of Acute and Chronic Retention in Men

Management of the Urologic Sepsis Syndrome

Shock Wave Lithotripsy for Renal and Ureteric Stones

Let the Games Begin (with EAU Approval)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Martin C. Michel European Urology Supplements

Bladder Cancer: A Major Public Health Issue

Back to the Future: Introduction and Conclusions

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

A Novel Treatment of Premature Ejaculation

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 51, Issue 1, Pages (January 2007)

Tim Schneider European Urology Supplements

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Ian Milsom European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

Optimal Testosterone Control and Eligard®

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

Pharmacotherapy in Stress and Mixed Incontinence

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Christian Stief European Urology Supplements

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Ureteropelvic Junction Obstruction

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Volume 53, Issue 5, Pages (May 2008)

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

LUTS and Sexual Dysfunction: Implications for Management of BPH

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

The Impact of Premature Ejaculation on Partners and Relationships

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

Diagnosis and Management of Cryptorchidism

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Jan Roigas European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Presentation transcript:

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean European Urology Supplements Volume 6, Issue 13, Pages 768-774 (July 2007) DOI: 10.1016/j.eursup.2007.04.006 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Reported level of distress. PE=premature ejaculation group; non-PE=non-premature ejaculation group. European Urology Supplements 2007 6, 768-774DOI: (10.1016/j.eursup.2007.04.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Reported level of satisfaction with sexual relationship (A) and reported perceived level of partner satisfaction with sexual relationship (B). PE=premature ejaculation group; non-PE=non-premature ejaculation group. European Urology Supplements 2007 6, 768-774DOI: (10.1016/j.eursup.2007.04.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Anticipated impact of increased intravaginal ejaculatory latency time on sexual relationship. PE=premature ejaculation. European Urology Supplements 2007 6, 768-774DOI: (10.1016/j.eursup.2007.04.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Therapies currently used to treat premature ejaculation. PE=premature ejaculation; SSRI=selective serotonin reuptake inhibitor; PDE5=phosphodiesterase type 5. European Urology Supplements 2007 6, 768-774DOI: (10.1016/j.eursup.2007.04.006) Copyright © 2007 European Association of Urology Terms and Conditions